The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment

Abstract Patients with chronic kidney diseases (CKD) are often treated with antiplatelets due to aberrant haemostasis. This study aimed to evaluate the bleeding risk with CKD patients undergoing pentoxifylline (PTX) treatment with/without aspirin. In this retrospective study, we used Taiwan’s Nation...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jing-Hung Fang, Yi-Chen Chen, Chung-Han Ho, Jui-Yi Chen, Chung-Hsi Hsing, Fu-Wen Liang, Chia-Chun Wu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a770523e0df6497e8fc1816ef4e748e7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a770523e0df6497e8fc1816ef4e748e7
record_format	dspace
spelling	oai:doaj.org-article:a770523e0df6497e8fc1816ef4e748e72021-12-02T16:32:12ZThe risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment10.1038/s41598-021-92753-42045-2322https://doaj.org/article/a770523e0df6497e8fc1816ef4e748e72021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92753-4https://doaj.org/toc/2045-2322Abstract Patients with chronic kidney diseases (CKD) are often treated with antiplatelets due to aberrant haemostasis. This study aimed to evaluate the bleeding risk with CKD patients undergoing pentoxifylline (PTX) treatment with/without aspirin. In this retrospective study, we used Taiwan’s National Health Insurance Research Database to identify PTX treated CKD patients. Patients undergoing PTX treatment after CKD diagnosis were PTX group. A 1:4 age, sex and aspirin used condition matched CKD patients non-using PTX were identified as controls. The outcome was major bleeding event (MBE: intracranial haemorrhage (ICH) and gastrointestinal tract bleeding) during 2-year follow-up period. Risk factors were estimated using Cox regression for overall and stratified analysis. The PTX group had higher MBE risk than controls (hazard ratio (HR) 1.19; 95% confidence interval (CI) 0.94–1.50). In stratified analysis, hyperlipidaemia was a significant risk factor (HR: 1.42; 95% CI 1.01–2.01) of MBE. A daily PTX dose larger than 800 mg, females, non-regular aspirin usage, and ischaemic stroke were risk factors for MBE in PTX group. When prescribing PTX in CKD patients, bleeding should be closely monitored, especially in those with daily dose more than 800 mg, aspirin users, and with a history of ischaemic stroke.Jing-Hung FangYi-Chen ChenChung-Han HoJui-Yi ChenChung-Hsi HsingFu-Wen LiangChia-Chun WuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jing-Hung Fang Yi-Chen Chen Chung-Han Ho Jui-Yi Chen Chung-Hsi Hsing Fu-Wen Liang Chia-Chun Wu The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
description	Abstract Patients with chronic kidney diseases (CKD) are often treated with antiplatelets due to aberrant haemostasis. This study aimed to evaluate the bleeding risk with CKD patients undergoing pentoxifylline (PTX) treatment with/without aspirin. In this retrospective study, we used Taiwan’s National Health Insurance Research Database to identify PTX treated CKD patients. Patients undergoing PTX treatment after CKD diagnosis were PTX group. A 1:4 age, sex and aspirin used condition matched CKD patients non-using PTX were identified as controls. The outcome was major bleeding event (MBE: intracranial haemorrhage (ICH) and gastrointestinal tract bleeding) during 2-year follow-up period. Risk factors were estimated using Cox regression for overall and stratified analysis. The PTX group had higher MBE risk than controls (hazard ratio (HR) 1.19; 95% confidence interval (CI) 0.94–1.50). In stratified analysis, hyperlipidaemia was a significant risk factor (HR: 1.42; 95% CI 1.01–2.01) of MBE. A daily PTX dose larger than 800 mg, females, non-regular aspirin usage, and ischaemic stroke were risk factors for MBE in PTX group. When prescribing PTX in CKD patients, bleeding should be closely monitored, especially in those with daily dose more than 800 mg, aspirin users, and with a history of ischaemic stroke.
format	article
author	Jing-Hung Fang Yi-Chen Chen Chung-Han Ho Jui-Yi Chen Chung-Hsi Hsing Fu-Wen Liang Chia-Chun Wu
author_facet	Jing-Hung Fang Yi-Chen Chen Chung-Han Ho Jui-Yi Chen Chung-Hsi Hsing Fu-Wen Liang Chia-Chun Wu
author_sort	Jing-Hung Fang
title	The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
title_short	The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
title_full	The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
title_fullStr	The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
title_full_unstemmed	The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
title_sort	risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a770523e0df6497e8fc1816ef4e748e7
work_keys_str_mv	AT jinghungfang theriskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT yichenchen theriskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT chunghanho theriskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT juiyichen theriskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT chunghsihsing theriskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT fuwenliang theriskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT chiachunwu theriskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT jinghungfang riskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT yichenchen riskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT chunghanho riskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT juiyichen riskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT chunghsihsing riskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT fuwenliang riskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment AT chiachunwu riskofmajorbleedingeventinpatientswithchronickidneydiseaseonpentoxifyllinetreatment
_version_	1718383827047415808

The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment

Ejemplares similares